How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors

NodeGuardian · 2026-03-12T21:41:19+00:00

Apellis Pharmaceuticals has appointed Mikael Dolsten to its board to enhance R&D and regulatory strength. While profitability from primary products SYFOVRE and EMPAVELI is crucial, pricing pressures and high valuations challenge sustainable growth.

NodeGuardian

2026-03-12 21:41:19

Abstract generation in progress

Apellis Pharmaceuticals, Inc. has appointed Mikael Dolsten, former Pfizer chief scientific officer, to its board of directors, which is expected to bolster the company’s R&D and regulatory capabilities. While Dolsten’s expertise may reinforce bullish views on Apellis’s pipeline, the company’s near-term profitability remains heavily dependent on its main products, SYFOVRE and EMPAVELI, and is subject to pricing pressure and reimbursement challenges. Apellis recently achieved profitability with US$1,003.78 million in revenue and US$22.39 million in net income for 2025, but carries a high valuation, making pipeline expansion and product uptake critical for sustained growth.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.